Theravance Biopharma (TBPH) Current Deferred Revenue (2013 - 2023)

Theravance Biopharma (TBPH) has 11 years of Current Deferred Revenue data on file, last reported at $24000.0 in Q3 2023.

• On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $24000.0 in Q3 2023; TTM through Sep 2023 was $24000.0, a 0.0% change from a year earlier, with the FY2022 full-year figure at $24000.0, down 75.51% from the prior year.
• Current Deferred Revenue for Q3 2023 stood at $24000.0, roughly flat from $24000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for TBPH reached as high as $43.3 million in Q2 2019 and fell as low as $24000.0 in Q2 2022.
• Historically, Current Deferred Revenue has averaged $12.9 million across 5 years, with a median of $5.7 million in 2021.
• Across the five-year window, Current Deferred Revenue tumbled 99.58% in 2022 and changed 0.0% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $31.6 million in 2019, then slumped by 63.51% to $11.5 million in 2020, then plunged by 99.15% to $98000.0 in 2021, then slumped by 75.51% to $24000.0 in 2022, then changed by 0.0% to $24000.0 in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $24000.0 in Q3 2023, $24000.0 in Q2 2023, and $24000.0 in Q1 2023.